GeoVax Announces Peer-Related Publication of Preclinical Data Showing 100% Protection with a Single Inoculation for Sudanese Ebola Virus Vaccine Candidate in NPJ Vaccines

GeoVax, Inc.

ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies for infectious diseases and cancer, today announced a peer-reviewed animal efficacy study of its Modified Vaccine Ankara (MVA) vector vaccine against Sudan Ebola Virus (SUDV). The study was published Nature Partner Journals (NPJ) vaccines.

GeoVax’s vaccine, MVA-VLP-SUDV, combines the immunogenicity advantages of a live attenuated vaccine vector with the true conformation of virus-like particles (VLPs). The vaccine represents the minimal components necessary for the formation of self-assembling VLPs in the vaccine recipient: the envelope glycoprotein GP and the matrix protein VP40. Guinea pigs vaccinated with a single dose of MVA-VLP-SUDV induced SUDV-specific binding and neutralizing antibody responses as well as Fc-mediated protective effects. These responses were enhanced by the second dose of vaccine. All vaccinated animals that received one or two doses of vaccine were protected from death and disease symptoms after challenge with a lethal dose of SUDV. These data demonstrate the potential of the MVA-VLP platform for single-dose protection and outbreak containment in emergency situations.

Mark J. Newman, PhD, Chief Scientific Officer of GeoVax, commented: “The GeoVax MVA-VLP platform enables the design of vaccines to present the immune system with multiple viral proteins that mimic an existing virus. The resulting immune responses are broadly functional, involving both antibody and T-cell effector function, resulting in optimal levels of efficacy at a single dose. These are ideal properties for vaccines that would support their use in the general population. The next phase of testing involving non-human primates is nearing completion and we look forward to these data.”

David Dodd, chairman and CEO of GeoVax, said: “This publication confirms the broad utility and value of the GeoVax MVA-VLP approach in providing a single-dose, highly effective vaccine against infectious diseases worldwide. Previously, our human Zaire Ebola virus vaccine demonstrated 100% protection, with a single dose, in a non-human primate model. The addition of Sudan Ebola virus to our hemorrhagic fever virus vaccine portfolio positions GeoVax to achieve leadership in this important area of ​​preventive healthcare. We look forward to providing further updates on our progress in this area. “.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies for infectious diseases and cancer using novel proprietary platforms. GeoVax’s product pipeline includes two Phase 2 clinical trials of GEO-CM04S1 for COVID-19 as a universal booster vaccine for mRNA vaccines approved by the US Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for the treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include prophylactic vaccines against Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as immunotherapies against many solid tumors. The company’s portfolio of wholly owned, jointly owned and licensed intellectual property includes more than 70 issued or pending patent applications spread across 20 patent families.

For more information about GeoVax, please visit our website: www.geovax.com.

Future announcements

This release contains forward-looking statements regarding GeoVax’s business plans. “believe”, “look forward”, “may”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “possible”, “goal”, “potential” ” the words ,” “may,” “will,” “expect” and similar words are intended to identify forward-looking statements as notified to us. We base these forward-looking statements primarily on our current expectations and projections regarding future events and financial trends, which are our may affect our financial condition, results of operations, business strategy and financial needs.Actual results may differ materially from those contained in this statement due to various factors, including: whether GeoVax will be able to obtain satisfactory results from current or future clinical trials of its investigational products, GeoVax immuno- Cancer products and preventive vaccines are necessary responses and those products or vaccines are effective if used effectively, GeoVax’s viral vector technology will adequately enhance immune responses to cancer antigens, GeoVax will be able to develop and produce its immuno-oncology products and prophylactic vaccines with the desired characteristics in a timely manner, GeoVax immuno-oncology products and prophylactic vaccines will be safe for human use, GeoVax vaccines effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and prophylactic vaccines will receive the necessary regulatory approvals to be licensed and marketed, GeoVax will raise the capital required to complete development. develop competitive products that are more effective or easier to use than GeoVax products, GeoVax may enter into favorable manufacturing and distribution agreements, and other factors beyond GeoVax’s control.

Additional information regarding our risk factors is contained in our registration statement on Form S-1 and periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date it is made. Factors or events may occur from time to time that could cause our actual results to differ, and it is impossible for us to predict all of them. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

The connection:
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220

Leave a Comment

Your email address will not be published.